Who
Shay Shemesh
Chief Dev. & Ops. Officer
Company insider
Files Form 4 as: Chief Dev. & Ops. Officer, Nuvectis Pharma.
In numbers
- Trades disclosed
- 24
- Buys
- 16
- Sells
- 0
- Bought
- $95K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 4 Feb 2022
- Last trade
- 6 Jan 2026
- Last filed
- 9 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Jan 2026filed 9 Jan 2026 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 6 Jan 2026filed 9 Jan 2026 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 2 Jan 2025filed 3 Jan 2025 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Code A | —150,000 at $0.00 | filing |
| 10 May 2024filed 13 May 2024 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $7,0341,113 at $6.32 | filing |
| 3 Jan 2024filed 5 Jan 2024 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Code A | —130,000 at $0.00 | filing |
| 21 Mar 2023filed 22 Mar 2023 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $5,036420 at $11.99 | filing |
| 15 Mar 2023filed 17 Mar 2023 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $7,176670 at $10.71 | filing |
| 12 Jan 2023filed 13 Jan 2023 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 21 Dec 2022filed 22 Dec 2022 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $3,825500 at $7.65 | filing |
| 17 Nov 2022filed 18 Nov 2022 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $1,080150 at $7.20 | filing |
| 16 Nov 2022filed 18 Nov 2022 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $1,065150 at $7.10 | filing |
| 23 Sep 2022filed 27 Sep 2022 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $1,731220 at $7.87 | filing |
| 2 Sep 2022filed 6 Sep 2022 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $3,357404 at $8.31 | filing |
| 1 Sep 2022filed 2 Sep 2022 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $12K1,530 at $8.07 | filing |
| 31 Aug 2022filed 2 Sep 2022 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $12K1,476 at $8.07 | filing |
| 20 May 2022filed 23 May 2022 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $4,962300 at $16.54 | filing |
| 17 May 2022filed 18 May 2022 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $2,776142 at $19.55 | filing |
| 16 May 2022filed 18 May 2022 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $1,928100 at $19.28 | filing |
| 12 May 2022filed 13 May 2022 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $52536 at $14.58 | filing |
| 12 May 2022filed 13 May 2022 | NVCT Nuvectis PharmaBiotechnology | SEC FORM 4 Bought | $19K1,184 at $15.85 | filing |
News
Nuvectis Pharma (NASDAQ:NVCT) Stock Falls 6.8% – Here's WhyNVCT · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Shay Shemesh; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.